{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:19:24Z","timestamp":1788970764994,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second\u2010line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes in dose and\/or injection intervals), to identify the predictive factors associated with updosing, and to improve CSU management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective, multicentric, real\u2010life observational study, including patients diagnosed with CSU and starting OMA. The data were collected at 0, 3, 6, and 9\u2009months. The primary endpoint was the frequency of OMA updosing at 3\u2009months. The secondary endpoints included an analysis of updosed patients' profile, and an assessment of OMA efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 153 patients. Twenty percent of patients were updosed at 3\u2009months, and 27% in total during the 9\u2010month follow\u2010up. Practitioners mainly chose to increase the frequency of injections (66%). At baseline, the updosed patients were more likely to have more severe CSU (UCT\u2009&lt;\u20094, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.030), a lower lymphocyte count (&lt;2000\/mm<jats:sup>3<\/jats:sup>, <jats:italic>p<\/jats:italic>\u2009=\u20090.037), and low IgE levels (&lt;70 UI\/mL, <jats:italic>p<\/jats:italic>\u2009=\u20090.024). The side effects of OMA were not more frequent after updosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>One in five patient underwent updosing within just 3\u2009months. OMA updosing is frequent in particular in cases of severe disease and low IgE blood levels.<\/jats:p><\/jats:sec>","DOI":"10.1111\/all.16256","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T07:29:29Z","timestamp":1721978969000},"page":"2448-2457","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study"],"prefix":"10.1111","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2534-6976","authenticated-orcid":false,"given":"Guillaume","family":"Pierrard","sequence":"first","affiliation":[{"name":"CHU Lille, University Lille Service de Dermatologie  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bernier","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Nantes Service de Dermatologie  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Du\u2010Thanh","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Montpellier Service de Dermatologie  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Bara","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Le Mans Service de Dermatologie  Le Mans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-6658","authenticated-orcid":false,"given":"Ang\u00e8le","family":"Soria","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"Sorbonne Universit\u00e9 Service de Dermatologie et d'Allergologie, H\u00f4pital Tenon  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Castelain","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Besan\u00e7on Service de Dermatologie  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boccon\u2010Gibod","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Grenoble, Service de M\u00e9decine Interne et Immunologie Clinique Centre de Reference des Angi\u0153d\u00e8mes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Hacard","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Lyon Service Allergologie et Immunologie Clinique  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Delaunay","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"CHU Angers Service de Dermatologie Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"de\u00a0Montjoye","sequence":"additional","affiliation":[{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"Department of Dermatology, Cliniques Universitaires Saint\u2010Luc Universit\u00e9 Catholique de Louvain  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Staumont\u2010Salle","sequence":"additional","affiliation":[{"name":"CHU Lille, University Lille Service de Dermatologie  Lille France"},{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"U1286 Inserm INFINITE Institute for Translational Research in Inflammation  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8930-1042","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Dezoteux","sequence":"additional","affiliation":[{"name":"CHU Lille, University Lille Service de Dermatologie  Lille France"},{"name":"French Chronic Urticaria Study Group (GUS)  Paris France"},{"name":"U1286 Inserm INFINITE Institute for Translational Research in Inflammation  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19561"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15030"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15090"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.032"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3447"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000491530"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.05.059"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2019.40.4230"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211065870"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411328"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13936"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526205"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087491"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13754"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00761-z"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08794-6"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.02.283"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.147"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.022"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13675"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.05.005"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.08.033"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.563840"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12975"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072639"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000529250"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12752"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19312"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15248"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.31744\/einstein_journal\/2020AO5175"},{"issue":"3","key":"e_1_2_10_33_1","first-page":"112","article-title":"Clinical experience of a chronic urticaria referral university center. Eur Ann allergy","volume":"52","author":"Andrade Coelho Dias G","year":"2020","journal-title":"Clin Immunol"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.139"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13838"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.06.026"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.08.025"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15589"},{"issue":"3","key":"e_1_2_10_39_1","first-page":"170","article-title":"Efficacy and safety of omalizumab updosing in chronic urticaria: a retrospective study","volume":"21","author":"Hapa FA","year":"2023","journal-title":"Skinmed"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.05.033"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.16256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:37:19Z","timestamp":1758087439000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.16256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/all.16256"],"URL":"https:\/\/doi.org\/10.1111\/all.16256","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"2024-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}